Scarica l'app Stockscreener
91.93
19.51%
-22.29
Pre-mercato:
90.00
-1.93
-2.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$114.22
Aprire:
$114.68
Volume 24 ore:
7.32M
Relative Volume:
6.01
Capitalizzazione di mercato:
$9.63B
Reddito:
$628.56M
Utile/perdita netta:
$141.82M
Rapporto P/E:
72.96
EPS:
1.26
Flusso di cassa netto:
$142.60M
1 W Prestazione:
+57.63%
1M Prestazione:
+51.75%
6M Prestazione:
+96.64%
1 anno Prestazione:
+257.15%
Intervallo 1D:
$91.06
$114.71
Intervallo di 1 settimana:
$53.79
$117.33
Portata 52W:
$20.84
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Confronta CORT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
91.93 | 9.63B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
U.S. Markets Ended Tuesday Mixed As monday.com Led, Corcept Therapeutics Lagged - Barron's
Yum Brands (YUM) Seeks New CEO as Corcept (CORT) and Hut 8 (HUT) Shares Climb - GuruFocus
Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga
Daily Digest: State Farm's newest rate hike request; Stock soars on cancer results - The Business Journals
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal - TradingView
Corcept's relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint - Pharmafile
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? - Nasdaq
Truist Securities lifts Corcept Therapeutics target to $150 - Investing.com
Corcept Therapeutics (CORT) Surges 109% Following Positive Trial Results - GuruFocus
Corcept Therapeutics (CORT) Stock Surges Following Positive Tria - GuruFocus
Corcept Therapeutics stock target raised to $150 by H.C. Wainwright - Investing.com India
Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company - Seeking Alpha
Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday? - Yahoo Finance
Corcept Therapeutics Reaches Analyst Target Price - Nasdaq
Corcept Therapeutics Shares Surge 109% to $114.22 on Phase 3 Trial Breakthrough - TradingPedia
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement - Yahoo Finance
AIG, Corcept Therapeutics, Dow - TradingView
Corcept Therapeutics shares double on solid Phase 3 results for ovarian cancer treatment - Mugglehead Magazine
Corcept Therapeutics stock soars to all-time high of $95.42 By Investing.com - Investing.com South Africa
Corcept looks to NDA following strong phase III ovarian cancer data - BioWorld MedTech
Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity - insights.citeline.com
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings) - Benzinga
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast - Benzinga
Why Is Corcept (CORT) Stock Soaring Today - Yahoo Finance
Corcept’s ovarian cancer drug cuts disease progression in study, shares jump By Reuters - Investing.com
Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip - simplywall.st
Corcept's ovarian cancer drug cuts disease progression in study, shares jump - Reuters
NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute - Yahoo Finance
Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer - Endpoints News
Corcept Therapeutics's Options Frenzy: What You Need to Know - Benzinga
Corcept Therapeutics shares surge on positive late-stage ovarian cancer trial results - Proactive Investors
Corcept Therapeutics price target raised to $150 from $76 at Truist - TipRanks
Piper Sandler Raises Corcept Therapeutics' Price Target to $128 From $78, Maintains Overweight Rating - MarketScreener
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers - Yahoo Finance
Market movers: Mr Cooper, Newsmax, Corcept Therapeutics... - Proactive financial news
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $150 From $115, Maintains Buy Rating - MarketScreener
Corcept Therapeutics stock soars to all-time high of $95.42 - Investing.com
Corcept soars as ovarian cancer drug succeeds late-stage trial - TradingView
Sector Update: Health Care - TradingView
Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump - MarketScreener
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - MarketScreener
Corcept Therapeutics stock soars after successful Phase 3 trial - Investing.com
Corcept Therapeutics stock soars after successful Phase 3 trial By Investing.com - Investing.com UK
Corcept Therapeutics Says Primary Endpoint Met in Phase 3 Ovarian Cancer Drug Study; Shares Up Pre-Bell - MarketScreener
Corcept's ovarian cancer combination drug meets main goal in late-stage study - TradingView
Corcept reports key trial success in ovarian cancer treatment - Investing.com
Major Clinical Trial Success: New Ovarian Cancer Drug Shows 4.5-Month Survival Advantage - Stock Titan
Did Corcept Therapeutics Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateCORT - ACCESS Newswire
NewMax goes public, Corcept Therapeutics gains, Moderna under pressure - Yahoo Finance
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? - Yahoo Finance
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):